Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

NCT02939989 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: Sofosbuvir
DRUG: Glecaprevir/Pibrentasvir
DRUG: Ribavirin

Sponsor

AbbVie